FDA Approves Clinical Trial satantis anti-tumor drug IDH1 inhibitor HH2301

HH2301, a selective inhibitor of hectic acid dehydrogenase 1 (IDH1) mutants developed jointly by the Shanghai Institute of Drug Research and Hai and Biology, has recently been granted implicit clinical trial approval (IND) by the U.SFood and Drug AdministrationAdministration(
FDA) to treat the stem tumorofas of IDH1 mutations including advanced bile duct cancer, cartilage cartilify and gliomametabolic abnormality is one of the ten characteristics of malignant tumor, and targeted tumor metabolism is considered to be a new anti-tumor strategy with great potential, and has become a hot field in the research and development of new anti-tumor drugs in recent yearsIDH1 is a key speed-limiting enzyme in cell sugar metabolism, one of the most mutated metabolic enzymes found in human tumors to date, and has been found in a variety of tumors such as bile duct cancer, cartilage sarcoma, glioma and acute myeloid leukemiaStudies have shown that mutant IDH1 (mIDH1) acquires a new catalytic function that can catalyze the generation of alpha-ketone diacid (alpha-KG) (R)-2-hydroxydium acid (2-HG)2-HG is a recognized cancer metabolite that promotes tumor malignancy through a variety of mechanisms, such as influencing histone methylation levelsCurrently, two IDH inhibitors have been approved by the FDA for the treatment of acute myeloid leukemia with IDH1 or IDH2 mutations, but no target inhibitor has been approved to treat the stem tumor of IDH1 mutationHH2301 is a new, efficient and selective mIDH1 inhibitor developed jointly by Shanghai Pharmaceutical Research Institute and Haihe And BiologyIn recent years, the oncology pharmacology team of Shanghai Pharmaceutical Research Institute has laid out the emerging field of tumor metabolism, and set up several invivative anti-tumor drug efficacy research platforms for metabolic enzymesIn collaboration with the drug chemistry research team of hai and bio, the screening found the new mIDH1 selective inhibitor HH2301, and the therapeutic potential of the compound for IDH1 mutant solid tumors was confirmed in the invivical and external models, illustrating the significant advantages compared to the listed drugsSystematic non-clinical studies show that the compound has excellent invivity and anti-tumor activity, and has good pharmacokinetic properties and safety in all test genusIn the solid tumor xenotransplant model (PDX model) of patients with IDH1 mutation, HH2301 embodies significant antitumor activity and has good clinical application development prospects FDA Approves Clinical Trials of Anti-Tumor Drug IDH1 Inhibitors Network Source: Network